BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34363937)

  • 21. Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells.
    Zhang Y; Wang Q; Li L; Le Y; Liu L; Yang J; Li Y; Bao G; Yan L
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1205-1216. PubMed ID: 34074193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.
    Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A
    Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
    Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and
    Le Y; Gan Y; Fu Y; Liu J; Li W; Zou X; Zhou Z; Wang Z; Ouyang G; Yan L
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):555-564. PubMed ID: 31967481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
    Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
    Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and evaluation of new quinazolin-4-one derivatives as apoptotic enhancers and autophagy inhibitors with potent antitumor activity.
    ElZahabi HSA; Nafie MS; Osman D; Elghazawy NH; Soliman DH; El-Helby AAH; Arafa RK
    Eur J Med Chem; 2021 Oct; 222():113609. PubMed ID: 34119830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of Novel 3-Cyanopyridines as Survivin Modulators and Apoptosis Inducers.
    Sabour R; Harras MF; Mohamed Al Kamaly O; Altwaijry N
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33105831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
    Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
    Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and molecular docking studies of 2-(furan-2-yl)quinazolin-4-one derivatives as potential antiproliferative agents.
    Ahmed MF; Belal A
    Arch Pharm (Weinheim); 2015 Jul; 348(7):487-97. PubMed ID: 25921702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, anticancer evaluation and molecular docking of new benzothiazole scaffolds targeting FGFR-1.
    Abd El-Meguid EA; Mohi El-Deen EM; Moustafa GO; Awad HM; Nossier ES
    Bioorg Chem; 2022 Feb; 119():105504. PubMed ID: 34836644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and
    Alanazi MM; Alaa E; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Taghour MS; Eissa IH
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1732-1750. PubMed ID: 34325596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
    Srour AM; Ahmed NS; Abd El-Karim SS; Anwar MM; El-Hallouty SM
    Bioorg Med Chem; 2020 Sep; 28(18):115657. PubMed ID: 32828424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel rigid analogs of 2-naphthol with potent anticancer activity through multi-target topoisomerase I & II and tyrosine kinase receptor EGFR & VEGFR-2 inhibition mechanism.
    El-Mawgoud HKA; Fouda AM; El-Nassag MAA; Elhenawy AA; Alshahrani MY; El-Agrody AM
    Chem Biol Interact; 2022 Mar; 355():109838. PubMed ID: 35123995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and molecular modeling studies of 2-styrylquinazoline derivatives as EGFR inhibitors and apoptosis inducers.
    Amin NH; Elsaadi MT; Zaki SS; Abdel-Rahman HM
    Bioorg Chem; 2020 Dec; 105():104358. PubMed ID: 33074119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of molecular hybrids of phthalimide-triazole agents with potent selective MCF-7/HepG2 cytotoxicity: Synthesis, EGFR inhibitory effect, and metabolic stability.
    Ihmaid SK; Alraqa SY; Aouad MR; Aljuhani A; Elbadawy HM; Salama SA; Rezki N; Ahmed HEA
    Bioorg Chem; 2021 Jun; 111():104835. PubMed ID: 33798850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition.
    Fan C; Zhong T; Yang H; Yang Y; Wang D; Yang X; Xu Y; Fan Y
    Eur J Med Chem; 2020 Mar; 190():112108. PubMed ID: 32058239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and discovery of new 1,2,4-triazolo[4,3-c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors.
    Alesawy MS; Al-Karmalawy AA; Elkaeed EB; Alswah M; Belal A; Taghour MS; Eissa IH
    Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000237. PubMed ID: 33226150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.